22 November 2023
22 November 2023
It has been 20 years since the paroxetine scandal and trial reporting has come a long way since then but there are still flaws.
The termination was announced after the monitoring committee declared that the candidate was unlikely to meet its primary endpoint.
The new scheme will launch in 2024 and aims to save the National Health Service (NHS) £14bn over five years.
The 50,000-participant US trial joins another study currently underway in England in partnership with the NHS.
The company anticipates reporting topline findings from the trial in the first quarter of next year.
A specific, paediatric granulated formulation of leniolisib will be administered to the patients in the trial.
The open-label trial is designed to assess the efficacy and safety of NXC-201.
The trial will analyse whether early treatment with Silmitasertib hinders CAP progression.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
